Both high TIM-3 expression and low GZMB levels on total NK cells of diagnostic BM specimens predicted poor clinical outcomes, and low GZMB levels in TIM-3+ NK cells independently predicted poorer RFS in AML. This evidence concerns the gene GZMB and acute myeloid leukemia.